BASEL, Switzerland, Jan. 16, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that the U.S. Food…
BASEL, Switzerland, Jan. 8, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that it has appointed…
BASEL, Switzerland, Nov. 29, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation…
BASEL, Switzerland, Oct. 9, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the acquisition of GLyPharma Therapeutic Inc. (“GLyPharma”) for…
BASEL, Switzerland, August 9, 2018 – Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced it has completed a $60 million mezzanine financing led by Novo Holdings and…
